Zenkuda And Tabirafusp-Ted Meet Primary Endpoints In Pivotal Daybreak Trial In Wamd, With Zenkuda Demonstrating A Potential New Standard-Of-Care Profile
Kodiak Sciences Inc. NASDAQ:KOD
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
KOD drugs meet primary endpoints in DAYBREAK trial
Zenkuda and tabirafusp-ted met primary endpoints in the pivotal DAYBREAK trial in wet age-related macular degeneration.